Meta-Analysis Backs MRD as AML Trial Endpoint

(MedPage Today) -- Reaching measurable residual disease (MRD) negativity in acute myeloid leukemia (AML) was associated with improved survival outcomes and could be used as an endpoint to speed up trials of novel therapies, according to findings...